{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T18:39:17Z","timestamp":1764873557132,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T00:00:00Z","timestamp":1511913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality & Outcomes"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.mayocpiqo.2017.11.004","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T09:13:15Z","timestamp":1513761195000},"page":"69-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Complement Regulatory Genetic Mutations in the Setting of Autoimmune Thrombotic Thrombocytopenic Purpura: A Case Series"],"prefix":"10.1016","volume":"2","author":[{"given":"Shebli","family":"Atrash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Appalanaidu","family":"Sasapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumya","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Cottler-Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Motwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.mayocpiqo.2017.11.004_bib1","first-page":"187","article-title":"Thrombotic thrombocytopenic purpura","volume":"111","author":"Atrash","year":"2015","journal-title":"J\u00a0Ark Med Soc"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2017.11.004_bib2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.semnephrol.2013.08.001","article-title":"Overview of complement activation and regulation","volume":"33","author":"Noris","year":"2013","journal-title":"Semin Nephrol"},{"issue":"22","key":"10.1016\/j.mayocpiqo.2017.11.004_bib3","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocpiqo.2017.11.004_bib4","doi-asserted-by":"crossref","first-page":"E1445","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"31","author":"Maga","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.mayocpiqo.2017.11.004_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ki.2011.291","article-title":"Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance","volume":"81","author":"Tortajada","year":"2012","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2017.11.004_bib6","first-page":"182","article-title":"Acquired thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome successfully treated with eculizumab","volume":"30","author":"Sasapu","year":"2017","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2017.11.004_bib7","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09084.x","article-title":"Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura","volume":"157","author":"Chapin","year":"2012","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.mayocpiqo.2017.11.004_bib8","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1182\/blood-2013-03-487694","article-title":"Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies","volume":"121","author":"Chapin","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2017.11.004_bib9","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2017.11.004_bib10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2017.11.004_bib11","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2007-09-109876","article-title":"Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1\/CFHR3 deficiency","volume":"111","author":"J\u00f3zsi","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2017.11.004_bib12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2017.11.004_bib13","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1371\/journal.pgen.0030041","article-title":"Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome","volume":"3","author":"Zipfel","year":"2007","journal-title":"PLoS Genet"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2017.11.004_bib14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/DAD.0000000000000234","article-title":"Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome","volume":"37","author":"Magro","year":"2015","journal-title":"Am J Dermatopathol"}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality & Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454817301285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454817301285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:06:53Z","timestamp":1762870013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454817301285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S2542454817301285"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2017.11.004","relation":{},"ISSN":["2542-4548"],"issn-type":[{"type":"print","value":"2542-4548"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement Regulatory Genetic Mutations in the Setting of Autoimmune Thrombotic Thrombocytopenic Purpura: A Case Series","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2017.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}